What question did this study set out to answer?

This study aims to explore how oncogenic KRAS and BRAF mutations influence the composition and uptake of extracellular vesicles.

August 9, 2026Scientific ReportsOpen Access

Single-vesicle heterogeneity and uptake of extracellular vesicles affected by oncogenic KRAS and BRAF revealed by proteomics and nano-flow cytometry

View Full Paper

Ask AI

Bookmark

Authors

Randomized trial examines EV characteristics altered by KRAS and BRAF mutations, suggesting novel drug delivery methods.

This study aims to explore how oncogenic KRAS and BRAF mutations influence the composition and uptake of extracellular vesicles.
Comparative proteomics and uptake assays were conducted.
Nano-flow cytometry was utilized to analyze EV surface properties.
Disruption assays targeted CD44 and CSPG4 interactions with respective ligands.
Mutant EVs demonstrated increased levels of CD44, LSR, ITGB4, and CSPG4, enhancing uptake (p<0.01).
Disruption of CD44 and CSPG4 interactions significantly reduced EV internalization and altered trafficking patterns.
Doxorubicin-loaded mutant EVs showed improved nuclear delivery and increased cytotoxicity with a 20% higher efficacy than wild-type EVs.

Seo et al. (2026) studied this question.

View Full Paper

Ask AI

Bookmark